title: Response to the letter concerning the article "Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy….
authors.affiliation: mciurzynsk-i@op.pl.
authors.forename: Michał
authors.initials: M
authors.lastname: Ciurzyński
authors.forename: Marzanna
authors.initials: M
authors.lastname: Paczyńska
authors.forename: Piotr
authors.initials: P
authors.lastname: Sobieraj
authors.forename: Piotr
authors.initials: P
authors.lastname: Pruszczyk
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage; D006760:Hospitalization; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage; D011655:Pulmonary Embolism / Q000188:drug therapy; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban